Pfu DNA polymerase

REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

Retrieved on: 
Thursday, January 13, 2022
CDC, Vaccination, Webcast, Forward-looking statement, Technology, Degenerative disease, SPAC, SAN, Allergic rhinitis, Private Securities Litigation Reform Act, EMA, SEC, Petra, COVID-19, Plaque, Virus, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Death, Influenza, Pfu DNA polymerase, NASDAQ, Viral load, Calu-3, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, Infection, ELISA, Immunity, A549, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Omicron, Polyp, Trial of the century, Acquisition, Video game, Pharmaceutical industry, Vaccine, Online shopping

SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced it has observed significant decrease in viral load with prophylactic treatment of REVTx-99 in three independent in vitro single cell-based assay models of SARS-CoV-2 infection.

Key Points: 
  • Human primary bronchial/tracheal cells were expanded and treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour prior to infection.
  • Human alveolar epithelial cells (A549, Adenocarcinomic) were treated with 250 ng/mL REVTx-99 24 hours prior to infection.
  • These studies were conducted on behalf of Revelation by a third-party contract research laboratory specializing in viral activity assays.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

Retrieved on: 
Tuesday, January 11, 2022
CDC, Vaccination, Webcast, Forward-looking statement, Technology, Degenerative disease, SPAC, SAN, Allergic rhinitis, Private Securities Litigation Reform Act, EMA, SEC, Petra, COVID-19, Plaque, Virus, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Death, Influenza, Pfu DNA polymerase, NASDAQ, Viral load, Calu-3, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, Infection, ELISA, Immunity, A549, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Omicron, Polyp, Trial of the century, Acquisition, Video game, Pharmaceutical industry, Vaccine, Online shopping

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced it has observed significant decrease in viral load with prophylactic treatment of REVTx-99 in three independent in vitro single cell-based assay models of SARS-CoV-2 infection.

Key Points: 
  • Human primary bronchial/tracheal cells were expanded and treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour prior to infection.
  • Human alveolar epithelial cells (A549, Adenocarcinomic) were treated with 250 ng/mL REVTx-99 24 hours prior to infection.
  • These studies were conducted on behalf of Revelation by a third-party contract research laboratory specializing in viral activity assays.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

PFU America, Inc. Joins DNA Data Storage Alliance

Retrieved on: 
Monday, April 19, 2021
Biology, DNA replication, Life sciences, Branches of biology, PFU, Biotechnology, Illumina, Inc., Pfu DNA polymerase, DNA

b'SUNNYVALE, Calif., April 19, 2021 /PRNewswire/ -- PFU America, Inc. , based in Sunnyvale, California, a member of the PFU group of companies, announced it joined the DNA Data Storage Alliance , led by Twist Bioscience Corporation , Illumina, Inc ., Western Digital and Microsoft .

Key Points: 
  • b'SUNNYVALE, Calif., April 19, 2021 /PRNewswire/ -- PFU America, Inc. , based in Sunnyvale, California, a member of the PFU group of companies, announced it joined the DNA Data Storage Alliance , led by Twist Bioscience Corporation , Illumina, Inc ., Western Digital and Microsoft .
  • With its digitalization technology and experience, PFU will support the advancement of the DNA data storage ecosystem with the alliance members.\nCultural assets of art, history, and science are valuable information that need to be preserved for the future.
  • Because of these characteristics, DNA is attracting attention as an emerging technology to realize future data storage needs.\nEstablished in October 2020, the DNA Data Storage Alliance aims to drive awareness and adoption of DNA data storage through use cases and the development of an industrial roadmap.
  • And we believe the technology and experience we have developed in digitalization will help the DNA Data Storage Alliance achieve its goals.

PFU Joins Plug and Play in Silicon Valley to Connect with IoT Startups

Retrieved on: 
Wednesday, December 18, 2019
PFU, Pfu DNA polymerase

In order to innovate society we must innovate ourselves," said Mr. Kamata, President and CEO of PFU America.

Key Points: 
  • In order to innovate society we must innovate ourselves," said Mr. Kamata, President and CEO of PFU America.
  • "We're excited to add PFU to Plug and Play's platform which will grant startup companies a great opportunity to partner with PFU and scale through their network both domestically and internationally," says Sobhan Khani, Vice President of Plug and Play.
  • The Internet of Things program, one of Plug and Play's oldest industry-specific platforms, aims to connect high-quality startups with corporations ready to embrace the changes coming to their industry.
  • We provide active investments with 200 leading Silicon Valley VCs, and host more than 700 networking events per year.